RxDoctor Payments Data

Otto Goyco

Internal Medicine · Cumming, GANPI 1013990431

Payments from drug & device makers

$11,688in general payments, 2019–2025

Across 701 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • AbbVie$956
  • Pfizer$688
  • Boehringer Ingelheim$609
  • plus $6K from 39 others

What the payments were for

  • Food & beverage$11,35897%
  • Education$3303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,688 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$128,968
Medicare patients
463
Services billed
2,117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin89$98,644
MounjaroTirzepatide72$81,550
EliquisApixaban72$75,596
OzempicSemaglutide61$73,440
FarxigaDapagliflozin Propanediol83$70,941
LinzessLinaclotide38$32,024
TrulicityDulaglutide22$26,542
Tresiba Flextouch U-200Insulin Degludec33$20,482
Soliqua 100-33Insulin Glargine/Lixisenatide17$19,815
KerendiaFinerenone26$16,739
JanumetSitagliptin Phos/Metformin Hcl21$15,821
Hysingla ErHydrocodone Bitartrate19$15,103
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog36$13,594
MyrbetriqMirabegron13$13,172
SynjardyEmpagliflozin/Metformin Hcl12$8,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,040$108,09294 claims
Boehringer IngelheimJardiance, Synjardy$609$106,787101 claims
PfizerEliquis$688$75,59672 claims
AstraZenecaFarxiga, Symbicort$1,190$75,00299 claims
Novo NordiskOzempic$1,463$73,44061 claims
AbbVieLinzess, Synthroid$956$38,452105 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$547$19,81517 claims
BayerKerendia$312$16,73926 claims
MerckJanumet$300$15,82121 claims
Astellas Pharma US IncMyrbetriq$541$13,17213 claims
Collegium Pharmaceutical, Inc.Xtampza Er$143$6,77912 claims
Kowa Pharmaceuticals America, Inc.Bystolic$234$2,33513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →